VSTM250117C1000
- 0.00
- 0.000.00%
Verastem Newsroom
Citi Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $7
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $7
Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)
Express News | Applied Therapeutics Inc - Shoshana Shendelman Steps Down as CEO
Express News | Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Verastem Is Maintained at Outperform by Mizuho
Verastem Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Verastem Analyst Ratings
Verastem Oncology's Triplet Combination Shows No Dose-Limiting Toxicities In RAMP 203 Trial
Verastem Announces Preliminary Avutometinib and Sotorasib Data
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Announces Target Price $9
Express News | Verastem Inc - No Dose-Limiting Toxicities Observed in Triplet Combination
Express News | Verastem Oncology Provides a Clinical Update for Ramp 203 Trial in Advanced Kras G12C Mutant Non-Small Cell Lung Cancer
Express News | Verastem Inc : Mizuho Raises Target Price to $9 From $7
BTIG Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13
Verastem's Promising Drug Combination for LGSOC: Analyst Recommends Buy Rating
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
Verastem Inc. Reports Increased Operating Expenses and Net Loss
Byondis Appoints Louis Denis, M.D., as Chief Medical Officer